Bleeding characteristics of patients with congenital hemophilia and inhibitors: Data from a postmarketing study of recombinant activated factor VII (SMART-7)

¹Haemophilia Center, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy;

²Northern Ireland Haemophilia Centre, Belfast City Hospital, Belfast, Northern Ireland;

³Faculty of Medicine of Comenius University, University Hospital, Bratislava, Slovakia;

⁴Novo Nordisk A/S, Søborg, Denmark; and

⁵Marseille University Hospital, Pediatric Hematology Unit, Hopital d'enfants de la Timone, Marseille, France